Special Issue "Drug Repositioning"
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: closed (31 October 2013)
Prof. Dr. Louis M. Mansky
Institute for Molecular Virology, University of Minnesota, 18-242 Moos Tower, 515 Delaware St. SE, Minneapolis, MN 55455, USA
Interests: antiretroviral; nucleoside; mutation; drug synergy; therapeutic indices
A current way to decrease the cost and expedite the development of novel drugs is to use the strategy of drug repositioning (drug repurposing). This strategy involves the use of drugs that are clinically approved for one condition to treat a different condition. Drug repositioning can expedite drug development by making use of drugs whose toxicity and pharmacokinetic profiles have already been extensively characterized. Drug repositioning has been successfully used for the treatment of conditions such as cancer, obesity, and osteoporosis, as well as others. Much promise exists for the successful repositioning of other drugs.
Prof. Dr. Louis M. Mansky
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed Open Access monthly journal published by MDPI.
- drug repositioning
- drug repurposing
- indications discovery
- drug re-profiling
- therapeutic switching
- drug re-tasking
- indication expansion
- lifecycle extension
Article: Ritonavir-Mediated Induction of Apoptosis in Pancreatic Cancer Occurs via the RB/E2F-1 and AKT Pathways
Pharmaceuticals 2014, 7(1), 46-57; doi:10.3390/ph7010046
Received: 15 November 2013; in revised form: 20 December 2013 / Accepted: 2 January 2014 / Published: 9 January 2014| PDF Full-text (845 KB) | HTML Full-text | XML Full-text
Pharmaceuticals 2013, 6(10), 1304-1321; doi:10.3390/ph6101304
Received: 17 September 2013; in revised form: 6 October 2013 / Accepted: 8 October 2013 / Published: 11 October 2013| Cited by 1 | PDF Full-text (145 KB) | HTML Full-text | XML Full-text
Last update: 14 August 2013